Hyoscine pharmacology

Reading File

Finding Sources

Searching PubMed

hyoscine scopolamine pharmacology

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive information. Let me compile the full pharmacology answer.

Hyoscine (Scopolamine) - Pharmacology

1. Classification & Source

Hyoscine (L-scopolamine) is a naturally occurring tertiary amine belladonna alkaloid and competitive muscarinic receptor antagonist. It is derived primarily from Hyoscyamus niger (henbane) and is the L-isomer of hyoscyamine. It belongs to the Solanaceae plant family, along with atropine.

The name relates to its source: atropine is D,L-hyoscyamine; hyoscine is L-hyoscine (scopolamine).

- Goodman & Gilman's Pharmacological Basis of Therapeutics

2. Mechanism of Action

Hyoscine competitively and reversibly blocks muscarinic (M) receptors at the orthosteric acetylcholine (ACh) binding site. The antagonism is surmountable - increasing ACh concentration can overcome the block.

Blocks M1, M2, and M3 subtypes (non-selective among subtypes)
Inhibits responses to parasympathetic nerve stimulation and exogenously injected choline esters
At presynaptic receptors: blockade can paradoxically augment ACh release (presynaptic muscarinic receptors normally inhibit further ACh release), partially counteracting postsynaptic blockade

Key structural note: The intact tropine ester with a free OH group is essential for antimuscarinic activity. As a tertiary amine, hyoscine freely crosses the blood-brain barrier - unlike quaternary derivatives (e.g., hyoscine butylbromide/Buscopan) which do not.

- Goodman & Gilman's, p. Structure-Activity Relationships

3. Pharmacological Effects by System

CNS (KEY distinguishing feature vs. atropine)

Unlike atropine (which has minimal CNS effects at therapeutic doses), hyoscine produces prominent CNS effects at low therapeutic doses. The reason is its greater penetration across the blood-brain barrier.

At therapeutic doses, hyoscine causes:

Sedation, drowsiness, fatigue
Amnesia (anterograde)
Dreamless sleep with reduction in REM sleep
Euphoria (potential for abuse)
Antiemesis - blocks neural pathways from the labyrinth to the vomiting centre, and reduces vestibular afferent transmission

With severe pain or in toxic doses, the opposite can occur: excitement, restlessness, hallucinations, delirium (similar to atropine toxicity).

The CNS depressant and amnesic effects were historically exploited in "twilight sleep" - preoperative/preanesthetic sedation in combination with morphine.

Cardiovascular

Transient bradycardia at low doses (0.4-0.6 mg range) - due to paradoxical peripheral M2 block or weak central vagomimetic effect
Tachycardia at higher doses - due to block of cardiac M2 receptors (vagal block), increasing SA node firing rate
AV nodal conduction is accelerated (useful to reverse vagally mediated bradycardia/AV block)

Gastrointestinal

Reduces salivary and gastric secretions (salivary glands are particularly sensitive)
Decreases GI motility and tone (spasmolytic effect on smooth muscle)
Used as antispasmodic for IBS and renal/biliary colic
Hyoscine butylbromide (Buscopan) does NOT enter CNS and is preferred for pure GI spasm

Respiratory

Reduces bronchial and tracheobronchial secretions
Causes bronchodilation (smooth muscle relaxation)
Used in palliative care for "death rattle" (retained secretions) - often compared with glycopyrronium

Urinary Tract

Decreases bladder tone and contraction amplitude
Can cause urinary retention (side effect)

Eye (topical)

Mydriasis (pupil dilation) - via blockade of iris sphincter
Cycloplegia (paralysis of ciliary muscle, loss of accommodation)
Duration is shorter than atropine but longer than homatropine/tropicamide

Sweat Glands

Inhibits eccrine sweat gland secretion (sympathetic cholinergic innervation)
Hot, dry skin; potential hyperthermia at high doses/ambient temperature

- Goodman & Gilman's Pharmacological Basis of Therapeutics

4. Dose-Response Hierarchy (Sensitivity of Organs)

Dose level	Effects
Low	↓ Salivary, bronchial, sweat secretions
Moderate	Mydriasis, cycloplegia, tachycardia
Higher	Urinary/GI tract relaxation
High	↓ Gastric motility and secretion

This hierarchy is not due to receptor affinity differences; hyoscine lacks subtype selectivity. It reflects varying degrees of parasympathetic tone, receptor reserve, and intramural reflex involvement in each organ.

5. Pharmacokinetics

Parameter	Details
Form	Tertiary amine - lipid-soluble
BBB penetration	Yes (readily)
Routes	SC, IM, IV, oral, transdermal patch
Transdermal patch	1.5 mg over 72 h (motion sickness)
Onset (transdermal)	~4 hours
Duration	Patch: ~72 h
Metabolism	Hepatic
Butylbromide form	Quaternary ammonium - does NOT cross BBB; acts peripherally only
Hydrobromide form	Tertiary - CNS-active; used parenterally or as patch

6. Formulations and Clinical Uses

Formulation	Name	Clinical Use
Hyoscine hydrobromide (patch)	Scopoderm	Motion sickness prevention
Hyoscine hydrobromide (injection)	-	Preanesthetic medication, palliative secretion control
Hyoscine butylbromide (oral/IV)	Buscopan	GI/ureteral spasm, IBS
Hyoscine hydrobromide (sublingual)	Kwells	Motion sickness

Clinical indications:

Motion sickness - most effective agent for short (4-6 h) to several-day exposures; best given prophylactically before motion begins
PONV (post-operative nausea/vomiting) prevention
Preanesthetic medication - sedation, amnesia, antisialagogue effect (reduces oral secretions before intubation)
Antispasmodic (butylbromide form) - IBS, renal colic, biliary colic
Palliative care - manages respiratory secretions ("death rattle"), N&V
Hypersalivation (e.g., clozapine-induced) - hydrobromide form

- Katzung's Basic and Clinical Pharmacology, 16th Ed.; Goodman & Gilman's

7. Adverse Effects

Predictable from its mechanism (mnemonic: "Can't see, can't spit, can't pee, can't shit, can't stay cool"):

Dry mouth (most sensitive/common)
Blurred vision, photophobia (cycloplegia/mydriasis)
Urinary retention (worse in BPH)
Constipation (reduced GI motility)
Tachycardia
Hyperthermia with anhidrosis
CNS effects (unique to hyoscine vs. peripheral anticholinergics): sedation, confusion, delirium, amnesia - especially prominent in elderly
Transdermal patch: local skin irritation

8. Contraindications and Cautions

Narrow-angle glaucoma - precipitates acute angle-closure attack via mydriasis
Benign prostatic hyperplasia - urinary retention risk
Myasthenia gravis - anticholinergic worsens neuromuscular blockade
Elderly patients - hyoscine hydrobromide should be avoided; risk of delirium, cognitive impairment, falls (Maudsley Guidelines caution)
Paralytic ileus / GI obstruction
Tachyarrhythmias

9. Hyoscine vs. Atropine: Key Differences

Feature	Hyoscine	Atropine
CNS at therapeutic dose	Sedation, amnesia	Minimal
BBB penetration	Greater	Less
Motion sickness	Excellent	Less effective
Heart rate effect	Similar tachycardia	Tachycardia
Preanesthetic use	Preferred (sedation + antisialagogue)	Less preferred
Duration of action	Longer	Shorter
Toxic CNS effect	Excitation/delirium	Excitation/delirium

10. Recent Evidence

A 2025 systematic review and meta-analysis (PMID 40197394) examined scopolamine's effects on memory and attention, relevant to its antidepressant and amnesic properties under active investigation.

Summary: Hyoscine is a non-selective competitive muscarinic antagonist whose key pharmacological distinction from atropine is its ready CNS penetration, producing sedation, amnesia, and effective antiemesis (especially for motion sickness) at therapeutic doses. The hydrobromide salt is CNS-active; the butylbromide salt (Buscopan) is peripherally restricted, making it a safer antispasmodic without central side effects. Dose titration must account for the sensitivity hierarchy across organs, and caution is mandatory in the elderly.

This is a shared conversation. Sign in to Orris to start your own chat.